Line-1: Implications in the etiology of cancer, clinical applications, and pharmacologic targets

• Published in: Mutation research. Reviews in mutation research 2018-10, Vol.778, p.51-60
• Main Authors: Khalid, M., Bojang, P., Hassanin, A.A.I., Bowers, E.C., Reyes-Reyes, E.M., Ramos, I.N., Ramos, K.S.
• Format: Article
• Language: English
• Subjects: Biomarker; ceRNAs; EMT; Pharmacology; Retrotransposition
• ISSN: 1383-5742; 1388-2139
• DOI: 10.1016/j.mrrev.2018.09.003

Long interspersed nuclear elements-1 (Line-1 or L1) accounts for approximately 17% of the human genome. The majority of L1s are inactive, but ∼100 remain retrotransposon competent (RC-L1) and able to retrotranspose through RNA intermediates to different locations of the genome. L1 is involved in both disease initiation and progression via retrotransposition dependent and independent mechanisms. Retrotransposed L1 sequences disrupt genetic loci at sites of insertion, while the activities of L1 si/piRNAs, mRNAs, and ORF1 and ORF2 proteins, and have been implicated in the etiology and progression of several human diseases. Despite these relationships, little is known about the clinical utility of L1 as a biomarker of disease initiation and progression, or the utility of small molecules to inhibit and reverse the harmful effects of L1. In this review, we discuss the life cycle of L1, somatic and germline inhibitions, the mechanisms of L1 retrotransposition dependent and independent disease initiation and progression, clinical utilities, and potential of L1s as pharmacologic targets for the treatment of cancer.